Recursion Pharmaceuticals Inc (RXRX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Recursion Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Recursion Pharmaceuticals Inc's ROI in the second quarter of 2026?
Recursion Pharmaceuticals Inc recorded a cumulative net loss of $-519 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -42.59%.
Within the Healthcare sector 423 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 3650, from total ROI ranking in the first quarter of 2026 at 4341.
Cerebral Cavernous Malformation (CCM) is a vascular disorder characterized by the presence of abnormal blood vessels in the brain, leading to symptoms such as seizures, headaches, and neurological deficits. The management of symptomatic CCM has long been a clinical challenge, prompting the need for novel therapeutic approaches. Recently, Recursion Pharmaceuticals announced promising results from Phase 2 trials of REC-994, the first investigational treatment specifically designed for symptomatic CCM. This article reviews the findings of these trials, emphasizing the drug s safety, tolerability, and exploratory efficacy.Cerebral Cavernous Malformation affects a significant number of individuals and poses severe health risks due to its unpredictable nature. Current treatments have focused primarily on surgical interventions for symptomatic cases, but the development of pharmacological options remains limited. REC-994 represents a groundbreaking therapeutic candidate, and its evaluation in clinical settings is crucial for advancing patient care in symptomatic CCM.
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day Recursion, a leading clinical stage TechBio company focused on decoding biology to industrialize drug discovery, is set to provide updated pipeline guidance to investors, analysts, and other stakeholders during their latest event, Download Day, on Monday, June 24, 2024. Despite recording a cumulative net loss of $-354 million in the first quarter of 2024, resulting in a negative return on investment (ROI) of -66.38%, Recursion Pharmaceuticals Inc aims to showcase its progress and potential during the event. Despite the financial challenges faced by Recursion Pharmaceuticals, the company remains determined to revolutionize drug discovery in the Healthcare sector. While it lags behind with a lower ROI compared to 385 other companies in the sector, there have been signs of improvement. The overall ranking of Recursion s ROI has shown progress, moving up to 2772 in the first quarter of 2024 from its previous position at 3301 in the fourth quarter of 2023.
Financial Statements
Recursion Pharmaceuticals Inc's II. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
